INVO Bioscience, Inc. (INVO) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, filed on April 16, 2024, by INVO Bioscience, Inc. (a Nevada corporation), serves to announce the issuance of a press release regarding financial results for the period ended December 31, 2023. The filing is categorized under Item 2.02 (Results of Operations and Financial Condition).
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the body of this 8-K document.
Material Changes
No material changes or comparative financial data versus prior periods are detailed in the text of this filing. The document solely acts as a notification that the results for the period ended December 31, 2023, have been released.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It explicitly states that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated April 16, 2024) for actual financial figures and operational highlights.
- Verify the specific revenue and net loss figures for the fiscal year ended December 31, 2023, as they are not present in this summary document.
- Check for any updated cash position or liquidity runway details in the full press release.
- Confirm if the press release includes any revised guidance for the current fiscal year.